Droxefa

Droxefa may be available in the countries listed below.

Ingredient matches for Droxefa

Cefadroxil

Cefadroxil is reported as an ingredient of Droxefa in the following countries:

• Indonesia

International Drug Name Search

Prémélange TS

Prémélange TS may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Prémélange TS

Oxytetracycline

Oxytetracycline hydrochloride (a derivative of Oxytetracycline) is reported as an ingredient of Prémélange TS in the following countries:

• France

Sulfadimethoxine

Sulfadimethoxine is reported as an ingredient of Prémélange TS in the following countries:

• France

International Drug Name Search

Serevent Diskus

In the US, Serevent Diskus (salmeterol systemic) is a member of the drug class adrenergic bronchodilators and is used to treat Asthma - Maintenance, Bronchospasm Prophylaxis and COPD - Maintenance.

US matches:

• Serevent Diskus


• Serevent Diskus inhalation

Ingredient matches for Serevent Diskus

Salmeterol

Salmeterol xinafoate (a derivative of Salmeterol) is reported as an ingredient of Serevent Diskus in the following countries:

• Austria


• Brazil


• Chile


• Czech Republic


• France


• Germany


• Iceland


• Israel


• Lithuania


• Luxembourg


• Sweden

International Drug Name Search

Robinul Forte

See also: Generic Robinul

Robinul Forte is a brand name of glycopyrrolate, approved by the FDA in the following formulation(s):

ROBINUL FORTE (glycopyrrolate - tablet; oral)

• 
  Manufacturer: SHIONOGI INC
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 2MG ^[RLD][AA]

Has a generic version of Robinul Forte been approved?

A generic version of Robinul Forte has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Robinul Forte and have been approved by the FDA:

glycopyrrolate tablet; oral

• 
  Manufacturer: BOCA PHARMA
  
  Approval date: October 19, 2011
  
  Strength(s): 2MG ^[AA]


• 
  Manufacturer: COREPHARMA
  
  Approval date: December 22, 2004
  
  Strength(s): 2MG ^[AA]


• 
  Manufacturer: DR REDDYS LABS LTD
  
  Approval date: March 21, 2008
  
  Strength(s): 2MG ^[AA]


• 
  Manufacturer: PAR PHARM
  
  Approval date: August 31, 2006
  
  Strength(s): 2MG ^[AA]


• 
  Manufacturer: RANBAXY
  
  Approval date: August 18, 2009
  
  Strength(s): 2MG ^[AA]


• 
  Manufacturer: VINTAGE
  
  Approval date: December 29, 2008
  
  Strength(s): 2MG ^[AA]


• 
  Manufacturer: WEST WARD
  
  Approval date: March 5, 2009
  
  Strength(s): 2MG ^[AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Robinul Forte. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for increasing the bioavailability of glycopyrrolate
  Patent 7,091,236
  Issued: August 15, 2006
  Inventor(s): Roberts; Alan & Venkataraman; Bala
  Assignee(s): Sciele Pharma, Inc.
  The invention relates to a method of increasing the bioavailability of glycopyrrolate by administration of a therapeutically effective amount of glycopyrrolate without food.
  
  Patent expiration dates:
  
  
  • April 24, 2024
    
    ✓ 
    Patent use: FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
  
  

See also...

• Robinul Forte Consumer Information (Wolters Kluwer)
• Robinul Forte Consumer Information (Cerner Multum)
• Robinul Forte Advanced Consumer Information (Micromedex)
• Glycopyrrolate Consumer Information (Wolters Kluwer)
• Glycopyrrolate Solution Consumer Information (Wolters Kluwer)
• Glycopyrrolate Tablets Consumer Information (Wolters Kluwer)
• Glycopyrrolate Consumer Information (Cerner Multum)
• Glycopyrrolate Advanced Consumer Information (Micromedex)
• Glycopyrrolate AHFS DI Monographs (ASHP)

Pedibene

Pedibene may be available in the countries listed below.

Ingredient matches for Pedibene

Terbinafine

Terbinafine hydrochloride (a derivative of Terbinafine) is reported as an ingredient of Pedibene in the following countries:

• Austria

International Drug Name Search

Urdox

Urdox may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

UK matches:

• URDOX (Ursodeoxycholic acid) 300mg Film-Coated Tablets (SPC)

Ingredient matches for Urdox

Ursodeoxycholic Acid

Ursodeoxycholic Acid is reported as an ingredient of Urdox in the following countries:

• Malta


• United Kingdom

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Nirapel

Nirapel may be available in the countries listed below.

Ingredient matches for Nirapel

Nitrendipine

Nitrendipine is reported as an ingredient of Nirapel in the following countries:

• Argentina

International Drug Name Search

Dynaxon

Dynaxon may be available in the countries listed below.

Ingredient matches for Dynaxon

Thiocolchicoside

Thiocolchicoside is reported as an ingredient of Dynaxon in the following countries:

• Turkey

International Drug Name Search

Dromer

Dromer may be available in the countries listed below.

Ingredient matches for Dromer

Nicardipine

Nicardipine hydrochloride (a derivative of Nicardipine) is reported as an ingredient of Dromer in the following countries:

• Japan

International Drug Name Search

Pilfud

Pilfud may be available in the countries listed below.

Ingredient matches for Pilfud

Minoxidil

Minoxidil is reported as an ingredient of Pilfud in the following countries:

• Bosnia & Herzegowina


• Croatia (Hrvatska)


• Serbia

International Drug Name Search

Medomycin

Medomycin may be available in the countries listed below.

Ingredient matches for Medomycin

Doxycycline

Doxycycline is reported as an ingredient of Medomycin in the following countries:

• Bahrain


• Cyprus


• Sri Lanka


• Sudan

Doxycycline hyclate (a derivative of Doxycycline) is reported as an ingredient of Medomycin in the following countries:

• Oman


• Taiwan

Doxycycline hydrochloride (a derivative of Doxycycline) is reported as an ingredient of Medomycin in the following countries:

• Singapore


• Thailand

International Drug Name Search

Lunesta

Lunesta is a brand name of eszopiclone, approved by the FDA in the following formulation(s):

LUNESTA (eszopiclone - tablet; oral)

• 
  Manufacturer: SUNOVION PHARMS INC
  
  Approval date: December 15, 2004
  
  Strength(s): 1MG, 2MG, 3MG ^[RLD]

Has a generic version of Lunesta been approved?

No. There is currently no therapeutically equivalent version of Lunesta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lunesta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Optically active 5H-pyrrolo[3, 4-B]pyrazine derivative, its preparation and pharmaceutical compositions containing it
  Patent 6,319,926
  Issued: November 20, 2001
  Inventor(s): Cotrel; Claude & Roussel; Gerard
  Assignee(s): Sepracor Inc.
  Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-di hydro-5H-pyrrolo[3,4-b]pyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillizers and hypnotics.
  
  Patent expiration dates:
  
  
  • January 16, 2012
    
    ✓ 
    Patent use: TREATMENT OF INSOMNIA
  
  



• 
  Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it
  Patent 6,444,673
  Issued: September 3, 2002
  Inventor(s): Claude; Cotrel & Gérard; Roussel
  Assignee(s): Sepracor Inc.
  Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillizers and hypnotics.
  
  Patent expiration dates:
  
  
  • February 14, 2014
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it
  Patent 6,864,257
  Issued: March 8, 2005
  Inventor(s): Cotrel; Claude & Roussel; Gérard
  Assignee(s): Sepracor Inc.
  Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillisers and hypnotics.
  
  Patent expiration dates:
  
  
  • August 30, 2012
    
    ✓ 
    Patent use: METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
  
  



• 
  Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing same
  Patent 7,381,724
  Issued: June 3, 2008
  Inventor(s): Cotrel; Claude & Roussel; Gerard
  Assignee(s): Sepracor Inc.
  Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillisers and hypnotics.
  
  Patent expiration dates:
  
  
  • January 16, 2012
    
    ✓ 
    Patent use: METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Lunesta Consumer Information (Drugs.com)
• Lunesta Consumer Information (Wolters Kluwer)
• Lunesta Consumer Information (Cerner Multum)
• Lunesta Advanced Consumer Information (Micromedex)
• Lunesta AHFS DI Monographs (ASHP)
• Eszopiclone Consumer Information (Wolters Kluwer)
• Eszopiclone Consumer Information (Cerner Multum)
• Eszopiclone Advanced Consumer Information (Micromedex)
• Zopiclone Advanced Consumer Information (Micromedex)
• Eszopiclone AHFS DI Monographs (ASHP)